24 August 2021
EFPIA Japan

Takahiko Iwaya to chair EFPIA JapanTOKYO – 24 August 2021 – EFPIA Japan announced today that Takahiko Iwaya (Sanofi K.K.)
has been appointed the new chair of EFPIA Japan, effective 1 September 2021. Current Chair
Heike Prinz will resign due to her new appointment outside the country in Bayer.
Yoshiaki Aono (Nippon Boehringer Ingelheim Co., Ltd.) who continues in his current position as
vice chair, and Leo Lee (Novartis Pharma K.K.) who has been newly appointed vice chair will
support Takahiko Iwaya in his new role.
Takahiro Iwaya, who will assume the new chair of EFPIA Japan, says, "As a super-aging society,Japan has to address increasing diversified healthcare needs, while also responding to urgent
public health challenges as a result of the COVID-19 pandemic. In order to strengthen thehealthcare system and promote innovation, it is important that EFPIA Japan continues to work
closely with our partners and facilitate constructive discussions between the government andindustry. I am honored and truly humbled to be appointed as chair of EFPIA Japan and will makethe most of my experience working as a government official and in the pharmaceutical industry tohelp fulfill the mission of EFPIA.”EFPIA Japan Board Members as of 1 September 2021
Chair

Takahiko Iwaya(Sanofi K.K.)

Vice Chairs

Yoshiaki Aono

(Nippon Boehringer Ingelheim Co., Ltd.)

Leo Lee(Novartis Pharma K.K.)

Ole Mølskov Bech

(Novo Nordisk Pharma Ltd.)

Stefan Woxström(AstraZeneca K.K.)

Paul Lirette(GlaxoSmithKline K.K.)

Julio Triana(Bayer Yakuhin, Ltd.)

Alexandre De Muralt(Merck Biopharma Co., Ltd.)

Kanako Kikuchi(UCB Japan Co., Ltd.)

Yasuhiro Nishimi(Nippon Boehringer Ingelheim Co., Ltd.)Board of Directors

Director General

EFPIA Japan
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017, Japan
Tel: +81-3- 6417-2032
Fax: +81-3- 6685-4870

NewNewNewAbout EFPIA Japan (http://efpia.jp/)
Established in April 2002, EFPIA Japan represents 21 R&D-based European pharmaceuticalcompanies operating in Japan. In 2020, combined sales from the member companies accounted
for roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to“Contribute to healthcare and patients in Japan through the early introduction of innovativemedicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in orderto improve Japanese healthcare for all.
About EFPIA (European Federation of Pharmaceutical Industries and Associations)(http://www.efpia.eu)
EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents thepharmaceutical industry operating in Europe. Through its direct membership of 36 national
associations and 39 leading pharmaceutical companies, EFPIA provides the voice of companies
committed to researching, developing and bringing new medicines to improve health and qualityof life around the world.
Contact:
Yuko Kidoguchi
EFPIA Japan Messaging & Communications Committee
1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268
Bayer Holding Ltd.
Tel: 03-6266-7757
Email: yuko.kidoguchi@bayer.com

EFPIA Japan
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017, Japan
Tel: +81-3- 6417-2032
Fax: +81-3- 6685-4870